1
|
Publicover J, Gaggar A, Jespersen JM, Halac U, Johnson AJ, Goodsell A, Avanesyan L, Nishimura SL, Holdorf M, Mansfield KG, Judge JB, Koshti A, Croft M, Wakil AE, Rosenthal P, Pai E, Cooper S, Baron JL. An OX40/OX40L interaction directs successful immunity to hepatitis B virus. Sci Transl Med 2019; 10:10/433/eaah5766. [PMID: 29563320 DOI: 10.1126/scitranslmed.aah5766] [Citation(s) in RCA: 26] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/18/2017] [Accepted: 01/03/2018] [Indexed: 12/19/2022]
Abstract
Depending on age of acquisition, hepatitis B virus (HBV) can induce a cell-mediated immune response that results in either cure or progressive liver injury. In adult-acquired infection, HBV antigens are usually cleared, whereas in infancy-acquired infection, they persist. Individuals infected during infancy therefore represent the majority of patients chronically infected with HBV (CHB). A therapy that can promote viral antigen clearance in most CHB patients has not been developed and would represent a major health care advance and cost mitigator. Using an age-dependent mouse model of HBV clearance and persistence in conjunction with human blood and liver tissue, we studied mechanisms of viral clearance to identify new therapeutic targets. We demonstrate that age-dependent expression of the costimulatory molecule OX40 ligand (OX40L) by hepatic innate immune cells is pivotal in determining HBV immunity, and that treatment with OX40 agonists leads to improved HBV antigen clearance in young mice, as well as increased strength of T cell responses in young mice and adult mice that were exposed to HBV when they were young and developed a CHB serological profile. Similarly, in humans, we show that hepatic OX40L transcript expression is age-dependent and that increased OX40 expression on peripheral CD4+ T cells in adults is associated with HBV clearance. These findings provide new mechanistic understanding of the immune pathways and cells necessary for HBV immunity and identify potential therapeutic targets for resolving CHB.
Collapse
Affiliation(s)
- Jean Publicover
- Department of Medicine, University of California, San Francisco (UCSF), San Francisco, CA 94143, USA.,UCSF Liver Center, UCSF, San Francisco, CA 94143, USA
| | - Anuj Gaggar
- Department of Medicine, University of California, San Francisco (UCSF), San Francisco, CA 94143, USA.,UCSF Liver Center, UCSF, San Francisco, CA 94143, USA
| | - Jillian M Jespersen
- Department of Medicine, University of California, San Francisco (UCSF), San Francisco, CA 94143, USA.,UCSF Liver Center, UCSF, San Francisco, CA 94143, USA
| | - Ugur Halac
- Department of Medicine, University of California, San Francisco (UCSF), San Francisco, CA 94143, USA.,UCSF Liver Center, UCSF, San Francisco, CA 94143, USA
| | - Audra J Johnson
- Department of Medicine, University of California, San Francisco (UCSF), San Francisco, CA 94143, USA.,UCSF Liver Center, UCSF, San Francisco, CA 94143, USA
| | - Amanda Goodsell
- Department of Medicine, University of California, San Francisco (UCSF), San Francisco, CA 94143, USA.,UCSF Liver Center, UCSF, San Francisco, CA 94143, USA
| | - Lia Avanesyan
- Liver Immunology Laboratory, California Pacific Medical Center Research Institute, San Francisco, CA 94115, USA.,Division of General and Transplant Hepatology, California Pacific Medical Center Research Institute, San Francisco, CA 94115, USA
| | | | - Meghan Holdorf
- Novartis Institute for Biomedical Research, Emeryville, CA 94619, USA
| | - Keith G Mansfield
- Discovery and Investigative Pathology, Novartis Institute for Biomedical Research, Cambridge, MA 02139, USA
| | - Joyce Bousquet Judge
- Discovery and Investigative Pathology, Novartis Institute for Biomedical Research, Cambridge, MA 02139, USA
| | - Arya Koshti
- Novartis Institute for Biomedical Research, Emeryville, CA 94619, USA
| | - Michael Croft
- La Jolla Institute for Allergy and Immunology, 9420 Athena Circle, La Jolla, CA 92037, USA
| | - Adil E Wakil
- Liver Immunology Laboratory, California Pacific Medical Center Research Institute, San Francisco, CA 94115, USA.,Division of General and Transplant Hepatology, California Pacific Medical Center Research Institute, San Francisco, CA 94115, USA
| | - Philip Rosenthal
- UCSF Liver Center, UCSF, San Francisco, CA 94143, USA.,Department of Pediatrics, UCSF, San Francisco, CA 94143, USA.,Department of Surgery, UCSF, San Francisco, CA 94143, USA
| | - Eric Pai
- Department of Medicine, University of California, San Francisco (UCSF), San Francisco, CA 94143, USA.,UCSF Liver Center, UCSF, San Francisco, CA 94143, USA
| | - Stewart Cooper
- UCSF Liver Center, UCSF, San Francisco, CA 94143, USA.,Liver Immunology Laboratory, California Pacific Medical Center Research Institute, San Francisco, CA 94115, USA.,Division of General and Transplant Hepatology, California Pacific Medical Center Research Institute, San Francisco, CA 94115, USA
| | - Jody L Baron
- Department of Medicine, University of California, San Francisco (UCSF), San Francisco, CA 94143, USA. .,UCSF Liver Center, UCSF, San Francisco, CA 94143, USA
| |
Collapse
|
2
|
Pierce AA, Duwaerts CC, Siao K, Mattis AN, Goodsell A, Baron JL, Maher JJ. CD18 deficiency improves liver injury in the MCD model of steatohepatitis. PLoS One 2017; 12:e0183912. [PMID: 28873429 PMCID: PMC5584926 DOI: 10.1371/journal.pone.0183912] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/18/2017] [Accepted: 08/14/2017] [Indexed: 02/06/2023] Open
Abstract
Neutrophils and macrophages are important constituents of the hepatic inflammatory infiltrate in non-alcoholic steatohepatitis. These innate immune cells express CD18, an adhesion molecule that facilitates leukocyte activation. In the context of fatty liver, activation of infiltrated leukocytes is believed to enhance hepatocellular injury. The objective of this study was to determine the degree to which activated innate immune cells promote steatohepatitis by comparing hepatic outcomes in wild-type and CD18-mutant mice fed a methionine-choline-deficient (MCD) diet. After 3 weeks of MCD feeding, hepatocyte injury, based on serum ALT elevation, was 40% lower in CD18-mutant than wild-type mice. Leukocyte infiltration into the liver was not impaired in CD18-mutant mice, but leukocyte activation was markedly reduced, as shown by the lack of evidence of oxidant production. Despite having reduced hepatocellular injury, CD18-mutant mice developed significantly more hepatic steatosis than wild-type mice after MCD feeding. This coincided with greater hepatic induction of pro-inflammatory and lipogenic genes as well as a modest reduction in hepatic expression of adipose triglyceride lipase. Overall, the data indicate that CD18 deficiency curbs MCD-mediated liver injury by limiting the activation of innate immune cells in the liver without compromising intrahepatic cytokine activation. Reduced liver injury occurs at the expense of increased hepatic steatosis, which suggests that in addition to damaging hepatocytes, infiltrating leukocytes may influence lipid homeostasis in the liver.
Collapse
Affiliation(s)
- Andrew A. Pierce
- Department of Medicine, University of California, San Francisco, San Francisco, California, United States of America
- Liver Center, University of California, San Francisco, San Francisco, California, United States of America
| | - Caroline C. Duwaerts
- Department of Medicine, University of California, San Francisco, San Francisco, California, United States of America
- Liver Center, University of California, San Francisco, San Francisco, California, United States of America
| | - Kevin Siao
- Department of Medicine, University of California, San Francisco, San Francisco, California, United States of America
- Liver Center, University of California, San Francisco, San Francisco, California, United States of America
| | - Aras N. Mattis
- Liver Center, University of California, San Francisco, San Francisco, California, United States of America
- Department of Pathology, University of California, San Francisco, San Francisco, California, United States of America
| | - Amanda Goodsell
- Department of Medicine, University of California, San Francisco, San Francisco, California, United States of America
- Liver Center, University of California, San Francisco, San Francisco, California, United States of America
| | - Jody L. Baron
- Department of Medicine, University of California, San Francisco, San Francisco, California, United States of America
- Liver Center, University of California, San Francisco, San Francisco, California, United States of America
| | - Jacquelyn J. Maher
- Department of Medicine, University of California, San Francisco, San Francisco, California, United States of America
- Liver Center, University of California, San Francisco, San Francisco, California, United States of America
- * E-mail:
| |
Collapse
|
3
|
Duwaerts CC, Amin AM, Siao K, Her C, Fitch M, Beysen C, Turner SM, Goodsell A, Baron JL, Grenert JP, Cho SJ, Maher JJ. Specific Macronutrients Exert Unique Influences on the Adipose-Liver Axis to Promote Hepatic Steatosis in Mice. Cell Mol Gastroenterol Hepatol 2017; 4. [PMID: 28649594 PMCID: PMC5472193 DOI: 10.1016/j.jcmgh.2017.04.004] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
BACKGROUND & AIMS The factors that distinguish metabolically healthy obesity from metabolically unhealthy obesity are not well understood. Diet has been implicated as a determinant of the unhealthy obesity phenotype, but which aspects of the diet induce dysmetabolism are unknown. The goal of this study was to investigate whether specific macronutrients or macronutrient combinations provoke dysmetabolism in the context of isocaloric, high-energy diets. METHODS Mice were fed 4 high-energy diets identical in calorie and nutrient content but different in nutrient composition for 3 weeks to 6 months. The test diets contained 42% carbohydrate (sucrose or starch) and 42% fat (oleate or palmitate). Weight and glucose tolerance were monitored; blood and tissues were collected for histology, gene expression, and immunophenotyping. RESULTS Mice gained weight on all 4 test diets but differed significantly in other metabolic outcomes. Animals fed the starch-oleate diet developed more severe hepatic steatosis than those on other formulas. Stable isotope incorporation showed that the excess hepatic steatosis in starch-oleate-fed mice derived from exaggerated adipose tissue lipolysis. In these mice, adipose tissue lipolysis coincided with adipocyte necrosis and inflammation. Notably, the liver and adipose tissue abnormalities provoked by starch-oleate feeding were reproduced when mice were fed a mixed-nutrient Western diet with 42% carbohydrate and 42% fat. CONCLUSIONS The macronutrient composition of the diet exerts a significant influence on metabolic outcome, independent of calories and nutrient proportions. Starch-oleate appears to cause hepatic steatosis by inducing progressive adipose tissue injury. Starch-oleate phenocopies the effect of a Western diet; consequently, it may provide clues to the mechanism whereby specific nutrients cause metabolically unhealthy obesity.
Collapse
Affiliation(s)
- Caroline C. Duwaerts
- Department of Medicine, University of California, San Francisco, California,The Liver Center, University of California, San Francisco, California
| | - Amin M. Amin
- Department of Medicine, University of California, San Francisco, California,The Liver Center, University of California, San Francisco, California
| | - Kevin Siao
- Department of Medicine, University of California, San Francisco, California,The Liver Center, University of California, San Francisco, California
| | - Chris Her
- Department of Medicine, University of California, San Francisco, California,The Liver Center, University of California, San Francisco, California
| | - Mark Fitch
- Department of Nutritional Sciences and Toxicology, University of California, Berkeley, California
| | | | | | - Amanda Goodsell
- Department of Medicine, University of California, San Francisco, California,The Liver Center, University of California, San Francisco, California
| | - Jody L. Baron
- Department of Medicine, University of California, San Francisco, California,The Liver Center, University of California, San Francisco, California
| | - James P. Grenert
- The Liver Center, University of California, San Francisco, California,Department of Pathology, University of California, San Francisco, California
| | - Soo-Jin Cho
- Department of Pathology, University of California, San Francisco, California
| | - Jacquelyn J. Maher
- Department of Medicine, University of California, San Francisco, California,The Liver Center, University of California, San Francisco, California,Correspondence Address correspondence to: Jacquelyn J. Maher, MD, Liver Center Laboratory, 1001 Potrero Avenue, Building 40, Room 4102, San Francisco, California 94110. fax: (415) 641-0517.Liver Center Laboratory1001 Potrero Avenue, Building 40, Room 4102San FranciscoCalifornia 94110
| |
Collapse
|
4
|
Yanagisawa H, Hashimoto M, Minagawa S, Takasaka N, Ma R, Moermans C, Ito S, Araya J, Budelsky A, Goodsell A, Baron JL, Nishimura SL. Role of IL-17A in murine models of COPD airway disease. Am J Physiol Lung Cell Mol Physiol 2016; 312:L122-L130. [PMID: 27913421 DOI: 10.1152/ajplung.00301.2016] [Citation(s) in RCA: 35] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/19/2016] [Revised: 11/22/2016] [Accepted: 11/22/2016] [Indexed: 12/20/2022] Open
Abstract
Small airway fibrosis is a major pathological feature of chronic obstructive pulmonary disease (COPD) and is refractory to current treatments. Chronic inflammatory cells accumulate around small airways in COPD and are thought to play a major role in small airway fibrosis. Mice deficient in α/β T cells have recently been shown to be protected from both experimental airway inflammation and fibrosis. In these models, CD4+Th17 cells and secretion of IL-17A are increased. However, a pathogenic role for IL-17 in specifically mediating fibrosis around airways has not been demonstrated. Here a role for IL-17A in airway fibrosis was demonstrated using mice deficient in the IL-17 receptor A (il17ra) Il17ra-deficient mice were protected from both airway inflammation and fibrosis in two different models of airway fibrosis that employ COPD-relevant stimuli. In these models, CD4+ Th17 are a major source of IL-17A with other expressing cell types including γδ T cells, type 3 innate lymphoid cells, polymorphonuclear cells, and CD8+ T cells. Antibody neutralization of IL-17RA or IL-17A confirmed that IL-17A was the relevant pathogenic IL-17 isoform and IL-17RA was the relevant receptor in airway inflammation and fibrosis. These results demonstrate that the IL-17A/IL-17 RA axis is crucial to murine airway fibrosis. These findings suggest that IL-17 might be targeted to prevent the progression of airway fibrosis in COPD.
Collapse
Affiliation(s)
- Haruhiko Yanagisawa
- Department of Pathology, University of California, San Francisco, California
| | - Mitsuo Hashimoto
- Department of Pathology, University of California, San Francisco, California
| | - Shunsuke Minagawa
- Department of Pathology, University of California, San Francisco, California
| | - Naoki Takasaka
- Department of Pathology, University of California, San Francisco, California
| | - Royce Ma
- Department of Pathology, University of California, San Francisco, California
| | - Catherine Moermans
- Department of Pathology, University of California, San Francisco, California
| | - Saburo Ito
- Department of Pathology, University of California, San Francisco, California
| | - Jun Araya
- Department of Internal Medicine, Respiratory Division, Jikei University, Tokyo, Japan; and
| | - Alison Budelsky
- Department of Inflammation Research, Amgen, Seattle, Washington
| | - Amanda Goodsell
- Department of Medicine, University of California, San Francisco, California
| | - Jody L Baron
- Department of Medicine, University of California, San Francisco, California
| | - Stephen L Nishimura
- Department of Pathology, University of California, San Francisco, California;
| |
Collapse
|
5
|
Publicover J, Jespersen JM, Johnson AJ, Nishimura SL, Goodsell A, Wakil AE, Rosenthal P, Pai E, Avanesyan L, Cooper S, Baron JL. Liver capsule: Age-influenced hepatic immune priming determines HBV infection fate: Implications from mouse to man. Hepatology 2016; 63:260. [PMID: 26457468 PMCID: PMC4806644 DOI: 10.1002/hep.28284] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/07/2022]
Affiliation(s)
- Jean Publicover
- Department of Medicine, University of California, San Francisco, CA,UCSF Liver Center, University of California, San Francisco, CA
| | - Jillian M. Jespersen
- Department of Medicine, University of California, San Francisco, CA,UCSF Liver Center, University of California, San Francisco, CA
| | - Audra J. Johnson
- Department of Medicine, University of California, San Francisco, CA,UCSF Liver Center, University of California, San Francisco, CA
| | | | - Amanda Goodsell
- Department of Medicine, University of California, San Francisco, CA,UCSF Liver Center, University of California, San Francisco, CA
| | - Adil E. Wakil
- Liver Immunology Laboratory, California Pacific Medical Center & Research Institute, San Francisco, CA,Division of Hepatology, California Pacific Medical Center & Research Institute, San Francisco, CA
| | - Philip Rosenthal
- UCSF Liver Center, University of California, San Francisco, CA,Department of Pediatrics, University of California, San Francisco, CA,Department of Surgery, University of California, San Francisco, CA
| | - Eric Pai
- Department of Medicine, University of California, San Francisco, CA,UCSF Liver Center, University of California, San Francisco, CA
| | - Lia Avanesyan
- Liver Immunology Laboratory, California Pacific Medical Center & Research Institute, San Francisco, CA,Division of Hepatology, California Pacific Medical Center & Research Institute, San Francisco, CA
| | - Stewart Cooper
- UCSF Liver Center, University of California, San Francisco, CA,Liver Immunology Laboratory, California Pacific Medical Center & Research Institute, San Francisco, CA,Division of Hepatology, California Pacific Medical Center & Research Institute, San Francisco, CA
| | - Jody L. Baron
- Department of Medicine, University of California, San Francisco, CA,UCSF Liver Center, University of California, San Francisco, CA
| |
Collapse
|
6
|
Hashimoto M, Yanagisawa H, Minagawa S, Sen D, Goodsell A, Ma R, Moermans C, McKnelly KJ, Baron JL, Krummel MF, Nishimura SL. A critical role for dendritic cells in the evolution of IL-1β-mediated murine airway disease. J Immunol 2015; 194:3962-9. [PMID: 25786688 DOI: 10.4049/jimmunol.1403043] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/05/2014] [Accepted: 02/16/2015] [Indexed: 01/09/2023]
Abstract
Chronic airway inflammation and fibrosis, known as airway remodeling, are defining features of chronic obstructive pulmonary disease and are refractory to current treatments. How and whether chronic inflammation contributes to airway fibrosis remain controversial. In this study, we use a model of chronic obstructive pulmonary disease airway disease utilizing adenoviral delivery of IL-1β to determine that adaptive T cell immunity is required for airway remodeling because mice deficient in α/β T cells (tcra(-/-)) are protected. Dendritic cells (DCs) accumulate around chronic obstructive pulmonary disease airways and are critical to prime adaptive immunity, but they have not been shown to directly influence airway remodeling. We show that DC depletion or deficiency in the crucial DC chemokine receptor ccr6 both protect from adenoviral IL-1β-induced airway adaptive T cell immune responses and fibrosis in mice. These results provide evidence that chronic airway inflammation, mediated by accumulation of α/β T cells and driven by DCs, is critical to airway fibrosis.
Collapse
Affiliation(s)
- Mitsuo Hashimoto
- Department of Pathology, University of California, San Francisco, San Francisco, CA 94110; and
| | - Haruhiko Yanagisawa
- Department of Pathology, University of California, San Francisco, San Francisco, CA 94110; and
| | - Shunsuke Minagawa
- Department of Pathology, University of California, San Francisco, San Francisco, CA 94110; and
| | - Debasish Sen
- Department of Pathology, University of California, San Francisco, San Francisco, CA 94110; and
| | - Amanda Goodsell
- Department of Medicine, University of California, San Francisco, San Francisco, CA 94110
| | - Royce Ma
- Department of Pathology, University of California, San Francisco, San Francisco, CA 94110; and
| | - Catherine Moermans
- Department of Pathology, University of California, San Francisco, San Francisco, CA 94110; and
| | - Kate J McKnelly
- Department of Pathology, University of California, San Francisco, San Francisco, CA 94110; and
| | - Jody L Baron
- Department of Medicine, University of California, San Francisco, San Francisco, CA 94110
| | - Matthew F Krummel
- Department of Pathology, University of California, San Francisco, San Francisco, CA 94110; and
| | - Stephen L Nishimura
- Department of Pathology, University of California, San Francisco, San Francisco, CA 94110; and
| |
Collapse
|
7
|
Minagawa S, Lou J, Seed RI, Cormier A, Wu S, Cheng Y, Murray L, Tsui P, Connor J, Herbst R, Govaerts C, Barker T, Cambier S, Yanagisawa H, Goodsell A, Hashimoto M, Brand OJ, Cheng R, Ma R, McKnelly KJ, Wen W, Hill A, Jablons D, Wolters P, Kitamura H, Araya J, Barczak AJ, Erle DJ, Reichardt LF, Marks JD, Baron JL, Nishimura SL. Selective targeting of TGF-β activation to treat fibroinflammatory airway disease. Sci Transl Med 2015; 6:241ra79. [PMID: 24944194 DOI: 10.1126/scitranslmed.3008074] [Citation(s) in RCA: 72] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
Airway remodeling, caused by inflammation and fibrosis, is a major component of chronic obstructive pulmonary disease (COPD) and currently has no effective treatment. Transforming growth factor-β (TGF-β) has been widely implicated in the pathogenesis of airway remodeling in COPD. TGF-β is expressed in a latent form that requires activation. The integrin αvβ8 (encoded by the itgb8 gene) is a receptor for latent TGF-β and is essential for its activation. Expression of integrin αvβ8 is increased in airway fibroblasts in COPD and thus is an attractive therapeutic target for the treatment of airway remodeling in COPD. We demonstrate that an engineered optimized antibody to human αvβ8 (B5) inhibited TGF-β activation in transgenic mice expressing only human and not mouse ITGB8. The B5 engineered antibody blocked fibroinflammatory responses induced by tobacco smoke, cytokines, and allergens by inhibiting TGF-β activation. To clarify the mechanism of action of B5, we used hydrodynamic, mutational, and electron microscopic methods to demonstrate that αvβ8 predominantly adopts a constitutively active, extended-closed headpiece conformation. Epitope mapping and functional characterization of B5 revealed an allosteric mechanism of action due to locking-in of a low-affinity αvβ8 conformation. Collectively, these data demonstrate a new model for integrin function and present a strategy to selectively target the TGF-β pathway to treat fibroinflammatory airway diseases.
Collapse
Affiliation(s)
- Shunsuke Minagawa
- Department of Pathology, University of California, San Francisco, San Francisco, CA 94110, USA
| | - Jianlong Lou
- Department of Anesthesia and Perioperative Care, University of California, San Francisco, San Francisco, CA 94110, USA
| | - Robert I Seed
- Department of Pathology, University of California, San Francisco, San Francisco, CA 94110, USA
| | - Anthony Cormier
- Department of Pathology, University of California, San Francisco, San Francisco, CA 94110, USA
| | - Shenping Wu
- The Keck Advanced Microscopy Laboratory, Department of Biochemistry and Biophysics, University of California, San Francisco, San Francisco, CA 94110, USA
| | - Yifan Cheng
- The Keck Advanced Microscopy Laboratory, Department of Biochemistry and Biophysics, University of California, San Francisco, San Francisco, CA 94110, USA
| | - Lynne Murray
- Department of Respiratory, Inflammation and Autoimmunity, MedImmune, Gaithersburg, MD 20878, USA. Department of Respiratory, Inflammation and Autoimmunity, MedImmune, Cambridge CB21 6GH, UK
| | - Ping Tsui
- Department of Respiratory, Inflammation and Autoimmunity, MedImmune, Gaithersburg, MD 20878, USA
| | - Jane Connor
- Department of Respiratory, Inflammation and Autoimmunity, MedImmune, Gaithersburg, MD 20878, USA
| | - Ronald Herbst
- Department of Respiratory, Inflammation and Autoimmunity, MedImmune, Gaithersburg, MD 20878, USA
| | - Cedric Govaerts
- Department of Respiratory, Inflammation and Autoimmunity, MedImmune, Cambridge CB21 6GH, UK
| | - Tyren Barker
- Department of Pathology, University of California, San Francisco, San Francisco, CA 94110, USA
| | - Stephanie Cambier
- Department of Pathology, University of California, San Francisco, San Francisco, CA 94110, USA
| | - Haruhiko Yanagisawa
- Department of Pathology, University of California, San Francisco, San Francisco, CA 94110, USA
| | - Amanda Goodsell
- Department of Medicine, University of California, San Francisco, San Francisco, CA 94110, USA
| | - Mitsuo Hashimoto
- Department of Pathology, University of California, San Francisco, San Francisco, CA 94110, USA
| | - Oliver J Brand
- Department of Pathology, University of California, San Francisco, San Francisco, CA 94110, USA
| | - Ran Cheng
- Department of Pathology, University of California, San Francisco, San Francisco, CA 94110, USA
| | - Royce Ma
- Department of Pathology, University of California, San Francisco, San Francisco, CA 94110, USA
| | - Kate J McKnelly
- Department of Pathology, University of California, San Francisco, San Francisco, CA 94110, USA
| | - Weihua Wen
- Department of Anesthesia and Perioperative Care, University of California, San Francisco, San Francisco, CA 94110, USA
| | - Arthur Hill
- Department of Surgery, University of California, San Francisco, San Francisco, CA 94110, USA
| | - David Jablons
- Department of Surgery, University of California, San Francisco, San Francisco, CA 94110, USA
| | - Paul Wolters
- Department of Medicine, University of California, San Francisco, San Francisco, CA 94110, USA
| | - Hideya Kitamura
- Department of Pathology, University of California, San Francisco, San Francisco, CA 94110, USA
| | - Jun Araya
- Department of Pulmonary Medicine, Jikei University, Tokyo 105 8461, Japan
| | - Andrea J Barczak
- Department of Medicine, University of California, San Francisco, San Francisco, CA 94110, USA
| | - David J Erle
- Department of Medicine, University of California, San Francisco, San Francisco, CA 94110, USA
| | - Louis F Reichardt
- Genetics, Development, and Behavioral Sciences, University of California, San Francisco, San Francisco, CA 94110, USA
| | - James D Marks
- Department of Anesthesia and Perioperative Care, University of California, San Francisco, San Francisco, CA 94110, USA
| | - Jody L Baron
- Department of Medicine, University of California, San Francisco, San Francisco, CA 94110, USA
| | - Stephen L Nishimura
- Department of Pathology, University of California, San Francisco, San Francisco, CA 94110, USA.
| |
Collapse
|
8
|
Publicover J, Gaggar A, Nishimura S, Van Horn CM, Goodsell A, Muench MO, Reinhardt RL, van Rooijen N, Wakil AE, Peters M, Cyster JG, Erle DJ, Rosenthal P, Cooper S, Baron JL. Age-dependent hepatic lymphoid organization directs successful immunity to hepatitis B. J Clin Invest 2013; 123:3728-39. [PMID: 23925290 DOI: 10.1172/jci68182] [Citation(s) in RCA: 72] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/11/2012] [Accepted: 06/06/2013] [Indexed: 02/06/2023] Open
Abstract
Hepatitis B virus (HBV) is a major human pathogen that causes immune-mediated hepatitis. Successful immunity to HBV is age dependent: viral clearance occurs in most adults, whereas neonates and young children usually develop chronic infection. Using a mouse model of HBV infection, we sought mechanisms underpinning the age-dependent outcome of HBV and demonstrated that hepatic macrophages facilitate lymphoid organization and immune priming within the adult liver and promote successful immunity. In contrast, lymphoid organization and immune priming was greatly diminished in the livers of young mice, and of macrophage-depleted adult mice, leading to abrogated HBV immunity. Furthermore, we found that CXCL13, which is involved in B lymphocyte trafficking and lymphoid architecture and development, is expressed in an age-dependent manner in both adult mouse and human hepatic macrophages and plays an integral role in facilitating an effective immune response against HBV. Taken together, these results identify some of the immunological mechanisms necessary for effective control of HBV.
Collapse
Affiliation(s)
- Jean Publicover
- Department of Medicine, UCSF, San Francisco, California, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
9
|
Kitamura H, Cambier S, Somanath S, Barker T, Minagawa S, Markovics J, Goodsell A, Publicover J, Reichardt L, Jablons D, Wolters P, Hill A, Marks JD, Lou J, Pittet JF, Gauldie J, Baron JL, Nishimura SL. Mouse and human lung fibroblasts regulate dendritic cell trafficking, airway inflammation, and fibrosis through integrin αvβ8-mediated activation of TGF-β. J Clin Invest 2011; 121:2863-75. [PMID: 21646718 DOI: 10.1172/jci45589] [Citation(s) in RCA: 142] [Impact Index Per Article: 10.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/28/2010] [Accepted: 04/13/2011] [Indexed: 12/27/2022] Open
Abstract
The airway is a primary portal of entry for noxious environmental stimuli that can trigger airway remodeling, which contributes significantly to airway obstruction in chronic obstructive pulmonary disease (COPD) and chronic asthma. Important pathologic components of airway remodeling include fibrosis and abnormal innate and adaptive immune responses. The positioning of fibroblasts in interstitial spaces suggests that they could participate in both fibrosis and chemokine regulation of the trafficking of immune cells such as dendritic cells, which are crucial antigen-presenting cells. However, physiological evidence for this dual role for fibroblasts is lacking. Here, in two physiologically relevant models - conditional deletion in mouse fibroblasts of the TGF-β-activating integrin αvβ8 and neutralization of αvβ8 in human COPD fibroblasts - we have elucidated a mechanism whereby lung fibroblast chemokine secretion directs dendritic cell trafficking, in a manner that is critically dependent on αvβ8-mediated activation of TGF-β by fibroblasts. Our data therefore indicate that fibroblasts have a crucial role in regulating both fibrotic and immune responses in the lung.
Collapse
Affiliation(s)
- Hideya Kitamura
- Department of Pathology, UCSF, San Francisco, California, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
10
|
Publicover J, Goodsell A, Nishimura S, Vilarinho S, Wang ZE, Avanesyan L, Spolski R, Leonard WJ, Cooper S, Baron JL. IL-21 is pivotal in determining age-dependent effectiveness of immune responses in a mouse model of human hepatitis B. J Clin Invest 2011; 121:1154-62. [PMID: 21393863 DOI: 10.1172/jci44198] [Citation(s) in RCA: 108] [Impact Index Per Article: 8.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/18/2010] [Accepted: 12/22/2010] [Indexed: 01/05/2023] Open
Abstract
HBV is a noncytopathic hepadnavirus and major human pathogen that causes immune-mediated acute and chronic hepatitis. The immune response to HBV antigens is age dependent: viral clearance occurs in most adults, while neonates and children usually develop chronic infection and liver disease. Here, we characterize an animal model for HBV infection that recapitulates the key differences in viral clearance between early life and adulthood and find that IL-21 may be part of an effective primary hepatic immune response to HBV. In our model, adult mice showed higher HBV-dependent IL-21 production in liver, compared with that of young mice. Conversely, absence of the IL-21 receptor in adult mice resulted in antigen persistence akin to that of young mice. In humans, levels of IL-21 transcripts were greatly increased in blood samples from acutely infected adults who clear the virus. These observations suggest a different model for the dichotomous, age dependent outcome of HBV infection in humans, in which decreased IL-21 production in younger patients may hinder generation of crucial CD8+ T and B cell responses. These findings carry implications for therapeutic augmentation of immune responses to HBV and potentially other persistent liver viruses.
Collapse
Affiliation(s)
- Jean Publicover
- Department of Medicine, UCSF, San Francisco, California, USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|
11
|
Barnett SW, Burke B, Sun Y, Kan E, Legg H, Lian Y, Bost K, Zhou F, Goodsell A, Zur Megede J, Polo J, Donnelly J, Ulmer J, Otten GR, Miller CJ, Vajdy M, Srivastava IK. Antibody-mediated protection against mucosal simian-human immunodeficiency virus challenge of macaques immunized with alphavirus replicon particles and boosted with trimeric envelope glycoprotein in MF59 adjuvant. J Virol 2010; 84:5975-85. [PMID: 20392857 PMCID: PMC2876657 DOI: 10.1128/jvi.02533-09] [Citation(s) in RCA: 73] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/03/2009] [Accepted: 03/18/2010] [Indexed: 12/19/2022] Open
Abstract
We have previously shown that rhesus macaques were partially protected against high-dose intravenous challenge with simian-human immunodeficiency virus SHIV(SF162P4) following sequential immunization with alphavirus replicon particles (VRP) of a chimeric recombinant VEE/SIN alphavirus (derived from Venezuelan equine encephalitis virus [VEE] and the Sindbis virus [SIN]) encoding human immunodeficiency virus type 1 HIV-1(SF162) gp140DeltaV2 envelope (Env) and trimeric Env protein in MF59 adjuvant (R. Xu, I. K. Srivastava, C. E. Greer, I. Zarkikh, Z. Kraft, L. Kuller, J. M. Polo, S. W. Barnett, and L. Stamatatos, AIDS Res. Hum. Retroviruses 22:1022-1030, 2006). The protection did not require T-cell immune responses directed toward simian immunodeficiency virus (SIV) Gag. We extend those findings here to demonstrate antibody-mediated protection against mucosal challenge in macaques using prime-boost regimens incorporating both intramuscular and mucosal routes of delivery. The macaques in the vaccination groups were primed with VRP and then boosted with Env protein in MF59 adjuvant, or they were given VRP intramuscular immunizations alone and then challenged with SHIV(SF162P4) (intrarectal challenge). The results demonstrated that these vaccines were able to effectively protect the macaques to different degrees against subsequent mucosal SHIV challenge, but most noteworthy, all macaques that received the intramuscular VRP prime plus Env protein boost were completely protected. A statistically significant association was observed between the titer of virus neutralizing and binding antibodies as well as the avidity of anti-Env antibodies measured prechallenge and protection from infection. These results highlight the merit of the alphavirus replicon vector prime plus Env protein boost vaccine approach for the induction of protective antibody responses and are of particular relevance to advancing our understanding of the potential correlates of immune protection against HIV infection at a relevant mucosal portal of entry.
Collapse
Affiliation(s)
- Susan W Barnett
- Novartis Vaccines and Diagnostics, 350 Massachusetts Avenue, Cambridge, MA 02139, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
12
|
Malyala P, Chesko J, Ugozzoli M, Goodsell A, Zhou F, Vajdy M, O'Hagan DT, Singh M. The potency of the adjuvant, CpG oligos, is enhanced by encapsulation in PLG microparticles. J Pharm Sci 2008; 97:1155-64. [PMID: 17683059 DOI: 10.1002/jps.21065] [Citation(s) in RCA: 44] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
The objective of this work was to evaluate the potency of the CpG containing oligonucleotide encapsulated within poly(lactide-co-glycolide), and coadministered with antigen adsorbed to poly(lactide-co-glycolide) microparticles (PLG particles). The formulations evaluated include, CpG added in soluble form, CpG adsorbed, and CpG encapsulated. The antigen from Neisseria meningitidis serotype B (Men B) was used in these studies. The immunogenicity of these formulations was evaluated in mice. Poly(lactide-co-glycolide) microparticles were synthesized by a w/o/w emulsification method in the presence of a charged surfactant for the formulations. Neisseria meningitidis B protein was adsorbed to the PLG microparticles, with binding efficiency and initial release measured. CpG was either added in the soluble or adsorbed or encapsulated form based on the type of formulation. The binding efficiency, loading, integrity and initial release of CpG and the antigen were measured from all the formulations. The formulations were then tested in mice for their ability to elicit antibodies, bactericidal activity and T cell responses. Encapsulating CpG within PLG microparticles induced statistically significant higher antibody, bactericidal activity and T cell responses when compared to the traditional method of delivering CpG in the soluble form.
Collapse
Affiliation(s)
- Padma Malyala
- Novartis Vaccines and Diagnostics, 4560 Horton St., M/S 4.355, Emeryville, CA 94608, USA.
| | | | | | | | | | | | | | | |
Collapse
|
13
|
Vajdy M, Srivastava I, Zhou F, Sun Y, Barnett S, Goodsell A. Dynamics of acute and memory mucosal and systemic immune responses against HIV‐1 envelope following immunizations through single or combinations of mucosal and systemic routes. FASEB J 2008. [DOI: 10.1096/fasebj.22.2_supplement.487] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
| | | | | | - Yi Sun
- Novartis Vaccines and DiagnosticsEmeryvilleCA
| | | | | |
Collapse
|
14
|
Goodsell A, Zhou F, Gupta S, Singh M, Malyala P, Kazzaz J, Greer C, Legg H, Tang T, Zur Megede J, Srivastava R, Barnett SW, Donnelly JJ, Luciw PA, Polo J, O'Hagan DT, Vajdy M. Beta7-integrin-independent enhancement of mucosal and systemic anti-HIV antibody responses following combined mucosal and systemic gene delivery. Immunology 2007; 123:378-89. [PMID: 17944930 DOI: 10.1111/j.1365-2567.2007.02702.x] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022] Open
Abstract
Vaccination strategies that can block or limit heterosexual human immunodeficiency virus (HIV) transmissions to local and systemic tissues are the goal of much research effort. Herein, in a mouse model, we aimed to determine whether the enhancement of antibody responses through mucosal and systemic immunizations, previously observed with protein-based vaccines, applies to immunizations with DNA- or RNA-based vectors. Intranasal (i.n.) followed by intramuscular (i.m.) immunizations (i.n./i.m.) with polylactide-coglycolide (PLG)-DNA microparticles encoding HIV-gag (PLG-DNA-gag) significantly enhanced serum antibody responses, compared with i.m., i.n. or i.m. followed by i.n. (i.m./i.n.) immunizations. Moreover, while i.n./i.m., i.n. or i.m./i.n. immunizations with PLG-DNA-gag resulted in genital tract antibody responses, i.m. immunizations alone failed to do so. Importantly, beta7-deficient mice developed local and systemic antibody responses following i.n./i.m. immunization, or immunization via any other route, similar to those of wild-type mice. To compare the DNA with an RNA delivery system, immunizations were performed with VEE/SIN-gag replicon particles, composed of Venezuelan equine encephalitis virus (VEE) replicon RNA and Sindbis surface structure (SIN). i.n./i.m., compared with any other immunizations, i.n./i.m. immunization with VEE/SIN-gag resulted in enhanced genital tract but not serum antibody responses. These data show for the first time that mucosal followed by systemic immunizations with gene delivery systems enhance B-cell responses independent of the mucosal homing receptors alpha4beta7 and alphaEbeta7.
Collapse
Affiliation(s)
- Amanda Goodsell
- Novartis Vaccines and Diagnostics, Inc., Emeryville, CA 94608, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
15
|
Greer CE, Zhou F, Goodsell A, Legg HS, Tang Z, zur Megede J, Uematsu Y, Polo JM, Vajdy M. Long-term protection in hamsters against human parainfluenza virus type 3 following mucosal or combinations of mucosal and systemic immunizations with chimeric alphavirus-based replicon particles. Scand J Immunol 2007; 66:645-53. [PMID: 17944814 DOI: 10.1111/j.1365-3083.2007.02019.x] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
No licensed vaccines are available to protect against parainfluenza virus type 3 (PIV3), a significant health risk for infants. In search of a safe vaccine, we used an alphavirus-based chimeric vector, consisting of Sindbis virus (SIN) structural proteins and Venezuelan equine encephalitis virus (VEE) replicon RNA, expressing the PIV3 hemagglutinin-neuraminidase (HN) glycoprotein (VEE/SIN-HN). We compared different routes of intramuscular (i.m.), intranasal (i.n.), or combined i.n. and i.m. immunizations with VEE/SIN-HN in hamsters. Six months after the final immunization, all hamsters were protected against live PIV3 i.n. challenge in nasal turbinates and lungs. This protection appeared to correlate with antibodies in serum, nasal turbinates and lungs. This is the first report demonstrating mucosal protection against PIV3 for an extended time following immunizations with an RNA replicon delivery system.
Collapse
Affiliation(s)
- C E Greer
- Novartis Vaccines and Diagnostics, Inc., Emeryville, CA 94608, USA
| | | | | | | | | | | | | | | | | |
Collapse
|
16
|
Vajdy M, Goodsell A, Zhou F, Singh M, Malyala P, Kazzaz J, Greer C, Megede JZ, Barnett S, O’Hagan D, Polo J. Beta7-integrin independent enhancement of mucosal and systemic anti-HIV antibody responses following combined mucosal and systemic gene delivery (41.1). The Journal of Immunology 2007. [DOI: 10.4049/jimmunol.178.supp.41.1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Abstract
Abstract
Vaccination strategies that can block or limit heterosexual HIV transmissions to local and systemic tissues are much sought for. Herein, in a mouse model, we aimed to determine whether the enhancement of antibody responses through mucosal and systemic immunizations, previously observed with protein-based vaccines, applies to immunizations with DNA- or RNA-based vectors. Intra-nasal (i.n.) followed by intra-muscular (i.m.) immunizations (i.n./i.m.) with PLG-DNA microparticles encoding HIV-gag (PLG-DNA-gag) significantly enhanced serum antibody responses, compared i.m., i.n. or i.m. followed by i.n. (i.m./i.n.), immunizations. Moreover, while i.n./i.m., i.n. or i.m./i.n. immunizations with PLG-DNA-gag resulted in genital tract antibody responses, i.m. immunizations alone failed to do so. Importantly, β7-deficient mice developed local and systemic antibody responses following i.n./i.m., or any other routes of immunization similar to wild type mice. To compare the DNA with an RNA delivery system, immunizations were performed with VEE/SIN-gag replicon particles, composed of Venezuelan Equine Encephalitis virus (VEE) replicon RNA and Sindbis surface structure (SIN). i.n./i.m., as compared to any other immunizations, with VEE/SIN-gag resulted in enhanced genital tract, but not serum antibody responses. These data show for the first time that mucosal followed by systemic immunizations with gene delivery systems enhance B cell responses independent of the mucosal homing receptors α4β7 or αEβ7.
Collapse
Affiliation(s)
- Michael Vajdy
- Vaccines Research, Novartis Vaccines and Diagnostics, Inc., 4560 Horton St. M/S 4.3, Emeryville, CA, 94608
| | - Amanda Goodsell
- Vaccines Research, Novartis Vaccines and Diagnostics, Inc., 4560 Horton St. M/S 4.3, Emeryville, CA, 94608
| | - Fengmin Zhou
- Vaccines Research, Novartis Vaccines and Diagnostics, Inc., 4560 Horton St. M/S 4.3, Emeryville, CA, 94608
| | - Manmohan Singh
- Vaccines Research, Novartis Vaccines and Diagnostics, Inc., 4560 Horton St. M/S 4.3, Emeryville, CA, 94608
| | - Padma Malyala
- Vaccines Research, Novartis Vaccines and Diagnostics, Inc., 4560 Horton St. M/S 4.3, Emeryville, CA, 94608
| | - Jina Kazzaz
- Vaccines Research, Novartis Vaccines and Diagnostics, Inc., 4560 Horton St. M/S 4.3, Emeryville, CA, 94608
| | - Catherine Greer
- Vaccines Research, Novartis Vaccines and Diagnostics, Inc., 4560 Horton St. M/S 4.3, Emeryville, CA, 94608
| | - Jan zur Megede
- Vaccines Research, Novartis Vaccines and Diagnostics, Inc., 4560 Horton St. M/S 4.3, Emeryville, CA, 94608
| | - Susan Barnett
- Vaccines Research, Novartis Vaccines and Diagnostics, Inc., 4560 Horton St. M/S 4.3, Emeryville, CA, 94608
| | - Derek O’Hagan
- Vaccines Research, Novartis Vaccines and Diagnostics, Inc., 4560 Horton St. M/S 4.3, Emeryville, CA, 94608
| | - John Polo
- Vaccines Research, Novartis Vaccines and Diagnostics, Inc., 4560 Horton St. M/S 4.3, Emeryville, CA, 94608
| |
Collapse
|
17
|
Nowak B, Goodsell A, Julli M. Residues of endosulfan in carp as an indicator of exposure conditions. Ecotoxicology 1995; 4:363-371. [PMID: 24197829 DOI: 10.1007/bf00118871] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/07/1994] [Accepted: 08/22/1994] [Indexed: 06/02/2023]
Abstract
: Endosulfan is an organochlorine insecticide, consisting of a mixture of two isomers: alpha and beta endosulfan. Endosulfan residues were determined in livers and gills of carp exposed to lethal and sublethal concentrations of endosulfan. The fish which were exposed to a lethal concentration contained the highest residue level in both liver and gills. In carp liver, the percentage of beta endosulfan in the residue decreased with time between exposure and collection of samples whereas the percentage of endosulfan sulphate increased. Carp killed by exposure to endosulfan had a significantly greater ratio of beta to alpha endosulfan and a significantly greater percentage of beta endosulfan in their livers. There was no such clear relationship for the residue composition in fish gills. The determination of residue composition, in particular the percentage of beta endosulfan or the ratio of beta to alpha isomers is recommended in investigations of fish kills when endosulfan is a suspected cause.
Collapse
Affiliation(s)
- B Nowak
- Department of Aquaculture, University of Tasmania at Launceston, PO Box 1214, 7250, Launceston, Tasmania, Australia
| | | | | |
Collapse
|